Area of research
Epidemiology · Hepatology
Research interest
Research focused on Fibrosis and Inflammation, with related work in Genotype, Cirrhosis, Placebo. Notable publications include 'Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial', 'Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised,...', and 'Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease'.
Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study
IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis
MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C
Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease
FibroGENE: A gene-based model for staging liver fibrosis
IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection